JP2018522888A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522888A5
JP2018522888A5 JP2018501345A JP2018501345A JP2018522888A5 JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5 JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
seq
nos
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522888A (ja
JP6807606B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042862 external-priority patent/WO2017011837A2/en
Publication of JP2018522888A publication Critical patent/JP2018522888A/ja
Publication of JP2018522888A5 publication Critical patent/JP2018522888A5/ja
Application granted granted Critical
Publication of JP6807606B2 publication Critical patent/JP6807606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501345A 2015-07-16 2016-07-18 多価及び多重特異性dr5結合融合タンパク質 Active JP6807606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020196358A Division JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性dr5結合融合タンパク質

Publications (3)

Publication Number Publication Date
JP2018522888A JP2018522888A (ja) 2018-08-16
JP2018522888A5 true JP2018522888A5 (enExample) 2019-07-04
JP6807606B2 JP6807606B2 (ja) 2021-01-06

Family

ID=57757772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018501345A Active JP6807606B2 (ja) 2015-07-16 2016-07-18 多価及び多重特異性dr5結合融合タンパク質
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性dr5結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性dr5結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性dr5結合融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性dr5結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性dr5結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性dr5結合融合タンパク質

Country Status (24)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3322734B1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR102760380B1 (enExample)
CN (2) CN114106178A (enExample)
AU (3) AU2016291701B2 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (3) IL307994A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2021111382A (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
US20210079106A1 (en) * 2017-12-28 2021-03-18 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
KR20220070215A (ko) * 2019-10-01 2022-05-30 엡실로겐 리미티드 하이브리드 항체
US20230287143A1 (en) * 2020-06-30 2023-09-14 Harbour Biomed (Shanghai) Co., Ltd Binding protein in fab-hcab structure
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CA3208641A1 (en) * 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
US20250215101A1 (en) * 2022-04-08 2025-07-03 Inhibrx Biosciences, Inc. DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
WO2023230432A1 (en) * 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy
CN117285644A (zh) * 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
US20260036590A1 (en) 2022-09-28 2026-02-05 Valink Therapeutics Ltd Multivalent proteins and screening methods
TW202515917A (zh) * 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241119A (en) * 1990-12-20 1993-06-25 Ixsys Inc Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 항체 및 그의 용도
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
JP2008532014A (ja) 2005-02-24 2008-08-14 セマインズ,インコーポレイティド 生物試料を分類するための組成物及び方法
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
JP2009518024A (ja) 2005-12-06 2009-05-07 ドマンティス リミテッド Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法
CA2638912A1 (en) 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
CA2706732A1 (en) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
ES2713864T3 (es) * 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en) 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
RS67588B1 (sr) 2009-12-14 2026-01-30 Ablynx Nv Antitela sa pojedinačnim varijabilnim domenom imunoglobulina protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011134060A1 (en) 2010-04-27 2011-11-03 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
CN103118706B (zh) * 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
US9771416B2 (en) 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CN103270047A (zh) 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
PH12014500380A1 (en) 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
JP2015531350A (ja) 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
KR20150082367A (ko) 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Similar Documents

Publication Publication Date Title
JP2018522888A5 (enExample)
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2020508655A5 (enExample)
JP2019116474A5 (enExample)
JP2021503455A5 (enExample)
JP2020525032A5 (enExample)
JP2019527553A5 (enExample)
JP2017504578A5 (enExample)
JP2018523493A5 (enExample)
JP2019532619A5 (enExample)
JP2010502183A5 (enExample)
JP2018520993A5 (enExample)
JP2009225799A5 (enExample)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2012501670A5 (enExample)
JP2018526981A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2013506428A5 (enExample)
JP2017149720A5 (enExample)
JP2012525829A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2018137110A (ru) Антитела против psma и их применение
JP2020514277A5 (enExample)
JPWO2020114480A5 (enExample)
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide